ArticleBMC oral health2026
Locally delivered dexpanthenol enhances bone regeneration in a rabbit defect model: Implications for oral and maxillofacial surgery.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone regeneration plays a critical role in oral and maxillofacial surgical procedures, including implant site preparation, periodontal defect management, and guided bone regeneration. Dexpanthenol (DXP), a well-tolerated derivative of pantothenic acid with antioxidant and wound-healing properties, has demonstrated beneficial effects in soft tissue repair; however, its potential role in bone regeneration remains insufficiently explored. Therefore, this study aimed to evaluate the effects of locally delivered DXP on bone healing using a standardized rabbit defect model.
methodsThis in vivo experimental study employed an intra-animal paired tibial defect model in eight adult male New Zealand White rabbits. Two standardized monocortical defects (6 mm in diameter and 8 mm in depth) were created in the right tibia of each animal. One defect was treated with a gelatin sponge (GS) (control), while the adjacent defect received DXP-impregnated GS. After a 30-day healing period, histomorphometric analysis and immunohistochemical evaluation of vascular endothelial growth factor (VEGF) expression were performed.
resultsDXP-treated defects exhibited significantly improved bone healing parameters compared to controls, including increased total healing area, higher defect closure rate, new bone formation, elevated osteoblast counts, and enhanced collagen deposition (P < 0.001 for all). VEGF expression was also significantly higher in the DXP group (P < 0.001), suggesting increased angiogenesis-related activity. No significant difference was observed in osteoclast counts (P > 0.05).
conclusionsWithin the limitations of this experimental model, locally delivered dexpanthenol was associated with enhanced bone formation healing and increased VEGF expression. However, given the use of a non-craniofacial defect model and the absence of mechanistic analyses, these findings should be interpreted with caution. Further studies using clinically relevant models and molecular approaches are required to clarify the underlying mechanisms and translational potential of DXP in bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.